Fig. 5
From: Epigenetic synergy between decitabine and platinum derivatives
Correlation between gene expression and hypomethylation. a. Carboplatin did not induce hypomethylation of DNA. YB5 cells were treated with decitabine 25 nM, carboplatin 25 μM, and decitabine + carboplatin for 4 days, respectively. DNA methylation at LINE-1, CMV, and MLH1 promoter CpG islands was analyzed by bisulfite pyrosequencing. Statistical significance of Bonferroni-corrected t tests is shown by asterisks (***P < 0.001, ****P < 0.0001). b. Carboplatin induced cell cycle arrest in the G2/M phase. YB5 cells were treated as described above and cell cycle distribution in G0/G1, S, and G2/M was measured by flow cytometry after propidium iodide staining and analyzed with the Chi-square test (P < 0.0001). c. Decitabine induced hypomethylation and gene expression in a dose-dependent manner. YB5 and HL60 cells were treated with a variety of logarithmically equally spaced concentrations of decitabine ranging from 0.03 to 30 μM. DNA methylation (left x-axis, solid lines) and mRNA expression (right x-axis, dotted lines) of MLH1, PDLIM4, PGR, OLIG2, and NPM2 genes were measured by bisulfite pyrosequencing and qPCR, respectively